Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A lands $30mm for Meissa Vaccines

Executive Summary

Respiratory-focused Meissa Vaccines Inc. raised $30mm in its Series A financing from Morningside Ventures, which adds two board members. The company will use the funds to add to its team, for Phase I and II trials of its respiratory syncytial virus vaccine candidate, and for pipeline expansion. Meissa is developing therapies based on its synthetic biology and genetic engineering technologies.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies